Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Are Market Conditions Setting Up A Biopharma M&A Wave?

EY Beyond Borders Report Predicts An Uptake Is Coming

Executive Summary

A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.

You may also be interested in...



Cash Runways Dry Up, Creating A ‘Complex’ Road Ahead For Biotech

More than half of emerging biotech companies have less than two years of cash to fund operations, according to EY’s Beyond Borders report.

M&A Has Been Down, But EY Argues Conditions Are Right For An Uptick In 2023

Despite concerns about the impact of the Inflation Reduction Act and constraining factors like inflation, EY believes more than $1.4tn in life sciences industry “firepower” should result in increased deal-making this year.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: a look a top executive compensation; BioMarin preps for Roctavian’s EU debut; Argenx eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and J&J’s Gorsky offers leadership lessons.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel